new england journal of medicine tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Read the full SURPASS-CVOT trial In the SUMMIT trial, researchers
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25


























